Immunogenetic insights into matching bivalent inactivated Payavax G79® for sustainable poultry vaccination against NDV-GVII and H9N2
Archives of Virology · 2026
DOI: 10.1007/s00705-025-06483-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Virology, 2026. Verfasst von Parisa Jamour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran. Hauptthemen laut MEDLINE: Newcastle disease virus, Influenza A Virus, H9N2 Subtype, Newcastle Disease, Influenza in Birds. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Paya Vaccine Tavana Co..
Abstract (Originalsprache)
Newcastle disease virus (NDV) and H9N2 avian influenza virus (AIV) have a severe impact on the poultry industry. This Iranian study evaluated Payavax G79®, an inactivated bivalent vaccine, in broiler chickens across five provinces. Vaccinated chicks showed robust antibody responses to both viruses via HI tests at 25 and 32 days post-vaccination. The vaccine provided complete protection against challenge with velogenic NDV genotype VII. However, H9N2 infection occurred on three farms, with 2% mortality. Molecular analysis of NDV isolates revealed amino acid substitutions in the hemagglutinin-neuraminidase protein that potentially enhance antigenicity. This study shows that Payavax G79® is highly immunogenic and provides significant protection against both NDV and H9N2 AIV under field conditions in Iran.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran.
- Division of Poultry Health and Diseases, Department of Clinical Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
- D.V.M Technical Manager of Hafez Dam Toos. Co, Mashhad, Iran.
- Veterinary Clinic Complex of Dr. Gholizadeh, Qazvin, Iran.
- Research and Development Department, Paya Vaccine Tavana Company, Alborz, Iran.
- Research and Development Department, Paya Vaccine Tavana Company, Alborz, Iran. Maryam.shafaati@gmail.com.
Förderung
- Paya Vaccine Tavana Co.
Zitieren
APA
Jamour, P., Babaeimarzangou, S. S., Daneshvar Hosseini, N., Gholizadeh Gigloo, M., Sheini Mehrabzadeh, R., Mohammadi, T., Khademi, Z., & Shafaati, M. (2026). Immunogenetic insights into matching bivalent inactivated Payavax G79® for sustainable poultry vaccination against NDV-GVII and H9N2. Archives of Virology. https://doi.org/10.1007/s00705-025-06483-3
Vancouver
Jamour P, Babaeimarzangou SS, Daneshvar Hosseini N, Gholizadeh Gigloo M, Sheini Mehrabzadeh R, Mohammadi T, et al. Immunogenetic insights into matching bivalent inactivated Payavax G79® for sustainable poultry vaccination against NDV-GVII and H9N2. Archives of Virology. 2026. doi:10.1007/s00705-025-06483-3
BibTeX
@article{Jamour2026,
author = {Jamour, Parisa and Babaeimarzangou, Seyed Sajjad and Daneshvar Hosseini, Nima and Gholizadeh Gigloo, Mostafa and Sheini Mehrabzadeh, Rasa and Mohammadi, Towhid and Khademi, Zohre and Shafaati, Maryam},
title = {Immunogenetic insights into matching bivalent inactivated Payavax G79® for sustainable poultry vaccination against NDV-GVII and H9N2},
journal = {Archives of Virology},
year = {2026},
doi = {10.1007/s00705-025-06483-3}
}
EUVIMED